TriangleHEALTH PROFESSIONAL · SOURCE READING
Maintenance Therapy After Induction Therapy for Mantle Cell Lymphoma
Source: Mantle Cell Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
The use of maintenance therapy with rituximab alone or combined with a Bruton tyrosine kinase (BTK) inhibitor after induction therapy or any consolidation has been the standard of care for mantle cell lymphoma (MCL). The duration of maintenance therapy has ranged from 3 years until time of disease relapse.
Continue within this section
Preserved source evidence · Not medical advice